רווח למניה בשנים עשר החודשים האחרונים: Ascentage Pharma Group International (AAPG)

Ascentage Pharma Group develops oncology drugs in the US and China, focusing on resistant forms of cancer. This daily chart from GURU.Markets illustrates earnings per share over the last 12 months, where the value -2.27 captures this metric. Proprietary molecules with high demand inertia ensure stable income, while the global expansion of Olverembatinib guarantees full patient retention.

This indicator determines the investment reliability of Ascentage Pharma Group by calculating the portion of net income attributable to a single ordinary share over the last 12 months. The current value of -2.27 for the annual earnings per share reflects the efficiency of innovation capitalization, including the implementation of AI models and robotic bio-screening to accelerate the development of anti-tumor drugs.